The present invention relates to an imidazoquinoline substituted phosphoric ester agonist, and a preparation therefor and an application thereof. Specifically, the compounds of the present invention have the structure shown in formula (I), wherein the definition of each group and substituent is as described in the description. Also disclosed in the present invention are a preparation method for the compound and use thereof as a TLR agonist.

##STR00001##

There are described RORγ modulators of the formula (I),

##STR00001##

and formula (II)

##STR00002##

or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. The compounds of this disclosure also relate to ##STR00001##
The use of these compounds as radio— and chemo—protectors is also described.

The present disclosure is directed to FXR agonists, pharmaceutical compositions thereof, and methods of using the same for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, either alone or in combination with thyroid receptor agonists.

Compounds of the general formula

##STR00001##

are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.

The present invention relates to novel compounds containing fluorinated end groups, to the use thereof as surface-active substances, and to compositions comprising these compounds.

An organic electrolytic solution includes a first lithium salt; an organic solvent; a bicyclic sulfate-based compound represented by Formula 1 below; and a monocyclic phosphate-based compound represented by Formula K1 below:

##STR00001## wherein in Formula 1, each of A.sub.1, A.sub.2, A.sub.3, and A.sub.4 is independently a covalent bond, a substituted or unsubstituted C.sub.1-C.sub.5 alkylene group, a carbonyl group, or a sulfinyl group, wherein both A.sub.1 and A.sub.2 are not a covalent bond and both A.sub.3 and A.sub.4 are not a covalent bond, and in Formula K1, each of A.sub.5 and A.sub.6 is independently a substituted or unsubstituted C.sub.1-C.sub.5 alkylene group.

Provided is a degradation inhibitor that delays the progress of the degradation reaction of 2ccPA and has an excellent stabilization effect by using a carbacyclic phosphatidic acid compound represented by formula (1):

##STR00001##

wherein R.sup.1 represents hydrogen, alkali metal, alkyl, arylalkyl, or aryl; bonds indicated by solid and dotted lines represent single or double bonds; wavy lines represent single bonds; and when the single bond is adjacent to a double bond, the steric configuration is E-configuration, Z-configuration, or any mixture thereof.

A lithium battery including: a cathode; an anode; and an electrolyte between the cathode and the anode, wherein the cathode includes a cathode active material represented by Formula 1,
Li.sub.xNi.sub.yM.sub.1−yO.sub.2-zA.sub.z  Formula 1 wherein 0.95≤x≤1.2, 0.75≤y≤0.98, and 0≤z<0.2, M is Al, Mg, Mn, Co, Fe, Cr, V, Ti, Cu, B, Ca, Zn, Zr, Nb, Mo, Sr, Sb, W, Bi, or a combination thereof, and A is an element having an oxidation number of −1, −2, or −3, wherein each element of M is independently present in an amount of 0.02≤y≤0.3, wherein a total content of M is 0.02≤y≤0.3;
and wherein the electrolyte includes a lithium salt, a non-aqueous solvent, and a diallyl compound represented by Formula 2, ##STR00001## wherein L.sub.1 and L.sub.2 are each independently a single bond, a C.sub.1-C.sub.20 alkylene group, or a substituted or unsubstituted C.sub.2-C.sub.20 alkenylene group.

The present invention relates to a process for resolution of Chlocyphos of Formula (I) to obtain corresponding (S)- or (R)-isomers. The present invention further relates to a process of obtaining (S)-Chlocyphos using (R)-(+)-α-methylbenzylamine and (R)-Chlocyphos using (S)-α-methylbenzylamine. The said resolution process provides the corresponding isomer with chiral purity more than 98%.

##STR00001##